Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
KVHI KVH Industries Inc
BAC Bank of America Corp
BHC Bausch Health Companies Inc
ANPC AnPac Bio-Medical Science Co Ltd
TREX Trex Company Inc
VIVO Meridian Bioscience Inc
WASH Washington Trust Bancorp Inc
AWF AllianceBernstein Global High Income Fund Inc.
AVK Advent Convertible & Income Fund

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.


Last Trade
-0.63 (-1.04%)
B/A Size

Market Hours

Closing Price
Day's Change
0.00 (0.00%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:

Fish & Richardson Named 2020 Intellectual Property Boutique Firm of the Year by LMG Life Sciences; Wins Hatch-Waxman Impact Case of the Year

1:42 pm ET September 24, 2020 (PR Newswire) Print

Fish & Richardson has been named the 2020 Intellectual Property Boutique Firm of the Year by LMG Life Sciences. Fish was also awarded the Hatch-Waxman Impact Case of the Year Award - the second time in three years - for its ongoing success for client Gilead Sciences, Inc. in Idenix Pharmaceuticals et al. v. Gilead Sciences, Inc.

Fish recently closed the latest chapter in Gilead's ongoing battle with Idenix Pharmaceuticals when the Federal Circuit denied, in a precedential decision, Idenix's bid to reinstate a $2.5 billion verdict (en banc review denied April 2020). The court upheld Fish's argument that Gilead's landmark Sovaldi(R) and Harvoni(R) hepatitis C drugs were not liable for infringement, finding Idenix's patent invalid for not adequately explaining how to make the treatment. The appellate decision came 18 months after Fish reversed on JMOL the $2.5 billion jury verdict, which at the time was the largest patent damages award in history. The firm has represented Gilead over the past five years in this worldwide complex patent battle, which has spanned the U.S., the UK, Canada, Germany, Australia, and Norway.

Fish won another groundbreaking life sciences case for client Mayo, Athena Diagnostics Inc. v. Mayo Collaborative Services LLC, with the Federal Circuit affirming that an Athena patent on a method for diagnosing a rare autoimmune disorder was invalid. In denying en banc review, the Federal Circuit issued 86 pages of opinions. Fish also opposed Athena's certiorari petition by noting that the U.S. Supreme Court had already provided adequate guidance in its Mayo v. Prometheus decision - another Fish Mayo win that set up the two-part rule for patent-eligibility that is now used for all technologies. The court denied certiorari, which ended this closely-watched case in January 2020.

The world's most innovative life sciences companies, academic institutions and research organizations trust Fish's Life Sciences group - with its more than 115 attorneys and technical specialists with biology, chemistry or genetic engineering degrees, including over 50 attorneys with PhD's - to handle their most important and technically sophisticated work. Fish's litigation practice is known for its ability to handle massive, high-profile patent disputes requiring extensive global litigation coordination, and the firm is a leader in Hatch-Waxman litigation for branded pharmaceutical companies. The group's patent prosecution, counseling and transactions practice is one of the most active in the world, with over 1,700 life sciences patent applications filed in 2019. Over the last six years, Fish oversaw IP due diligence on over $50 billion worth of life sciences deals. The firm is also the most active firm at the Patent Trial and Appeal Board.

LMG Life Sciences is a guide to leading North American law firms and lawyers specializing in the life sciences industry.

Fish & Richardson, the premier global intellectual property law firm, is trusted by the world's most innovative and influential companies. From patent, trademark, and copyright prosecution and counseling to our full-service litigation practice, we work together to provide our clients with exceptional advocacy across the life cycle of intellectual property needs in the U.S. and around the world. Our deep bench of attorneys with first-chair trial experience in every technology makes us the go-to firm for the most technically complex cases. Fish was established in 1878, and now has more than 400 attorneys and technology specialists in the U.S., Europe, and China. Our success is rooted in our creative and inclusive culture, which values the diversity of people, experiences, and perspectives. For more information, visit or follow us at @FishRichardson.

Contact: Amy Blumenthal                     or Katie Abbott
         Blumenthal & Associates               Fish & Richardson P.C.
         (617) 879-1511                        (202) 220-6847       

View original content to download multimedia:

SOURCE Fish & Richardson

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.